Economic impact of cytomegalovirus in solid organ transplantation
- 1 December 2001
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 3, 14-19
- https://doi.org/10.1034/j.1399-3062.2001.00003.x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Human β‐Herpesvirus Interactions in Solid Organ Transplant RecipientsThe Journal of Infectious Diseases, 2001
- VALACICLOVIR PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION AND DISEASE IN RENAL TRANSPLANTATION: AN ECONOMIC EVALUATIONTransplantation, 2000
- Cost-Effectiveness Model of Cytomegalovirus Management Strategies in Renal TransplantationPharmacoEconomics, 2000
- Comparison of the efficacy and cost effectiveness of pre-emptive therapy as directed by CMV antigenemia and prophylaxis with ganciclovir in lung transplant recipientsThe Journal of Heart and Lung Transplantation, 2000
- THE ECONOMIC IMPACT OF CYTOMEGALOVIRUS INFECTION AFTER LIVER TRANSPLANTATIONTransplantation, 2000
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationThe New England Journal of Medicine, 1999
- HUMAN HERPESVIRUS 6 SERONEGATIVITY BEFORE TRANSPLANTATION PREDICTS THE OCCURRENCE OF FUNGAL INFECTION IN LIVER TRANSPLANT RECIPIENTSTransplantation, 1999
- Seroconversion to Human Herpesvirus 6 following Liver Transplantation Is a Marker of Cytomegalovirus DiseaseThe Journal of Infectious Diseases, 1997
- PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION IN LIVER TRANSPLANTATIONTransplantation, 1997
- CYTOMEGALOVIRUS DISEASE IS ASSOCIATED WITH INCREASED COST AND HOSPITAL LENGTH OF STAY AMONG ORTHOTOPIC LIVER TRANSPLANT RECIPIENTS1Transplantation, 1997